Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

0.0%

-86.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 3
1(33.3%)
3Total
N/A(2)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT04894643Not ApplicableRecruiting

Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer

Role: collaborator

NCT04600921Phase 3Terminated

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

Role: collaborator

NCT04875871Not ApplicableTerminated

Particle-based Partial Tumor Irradiation of Unresectable Bulky Tumors

Role: collaborator

NCT03171909Unknown

Austrian Registry on the Outcome of Monochorionic Pregnancies

Role: collaborator

All 4 trials loaded